Absci is trading at $9.65, up 5.12%, with the gain most consistent with broader market strength.
- The S&P 500 and Nasdaq are each up more than 0.5%.
- No clearly new company-specific announcement was found for October 26. Recent coverage mentions an AstraZeneca collaboration worth up to $247 million, but does not establish it as a new catalyst for the move.
- No volume data was provided.